Since its founding in 1997, the company has focused on the gut-kidney axis, creating science-based dietary supplements such as its flagship product, Renadyl. The AANP award honors organizations that demonstrate consistent support for practitioners and innovation within the field. According to Mike Kane, COO of Kibow Biotech, the recognition underscores the company’s alignment with patient-centered care models that prioritize long-term kidney health.

Beyond product development, the firm has maintained a presence in the naturopathic community through ongoing educational initiatives and research into how the intestinal microbiome influences renal function. By targeting inflammation and reducing harmful metabolites, the company’s portfolio—including the Kibow Fortis line—aims to support patients across various stages of care. The AANP selection committee highlighted this commitment to evidence-based practice and professional collaboration as the primary drivers for this year's distinction.